Treatment of Relapsed or Refractory t(8; 21) AML With Targeted AML1-ETO Neoantigen Cytotoxic T Cells (CTL)

NCT06499025 · clinicaltrials.gov ↗

EARLY_PHASE1

Phase

ENROLLING_BY_INVITATION

Status

16

Enrollment

OTHER

Sponsor class

Conditions

AML
t(8;21)
Neoantigen

Interventions

BIOLOGICAL: targeted AML1-ETO neoantigen cytotoxic T cells (CTL)
DRUG: Cyclophosphamide injection
DRUG: Decitabine Injection
DRUG: Liposome mitoxantrone

Sponsor

BGI, China

Collaborators

[object Object]